FDA Approves AbbVie’s Vraylar As Adjunct Treatment For Major Depressive Disorder

The U.S. Food and Drug Administration (FDA) approved AbbVie’s Vraylar (cariprazine) as an adjunctive treatment for adults with major depressive disorder (MDD) who have not fully responded to antidepressant therapy (ADT). This is the fourth indication for Vraylar. It is FDA-approved to treat adults with depressive, acute manic and mixed episodes associated with bipolar I disorder, as well as schizophrenia.

Cariprazine is co-developed by AbbVie and Gedeon Richter Plc. The medication is the first and only dopamine and serotonin partial agonist FDA-approved for the most common forms of depression. More than 8,000 patients worldwide . . .